S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307
Withdrawn
National Cancer Institute (NCI)
2008-10-01
RATIONALE: Gathering information over time from imaging and laboratory tests of women
receiving bisphosphonates for breast cancer may help doctors learn more about long-term bone
quality and plan the best treatment. Tetracycline hydrochloride and demeclocycline
hydrochloride can mark the new growth of the bone, so it may be seen better under a
microscope.
PURPOSE: This clinical trial is studying long-term bone quality in women with breast cancer
enrolled on clinical trial SWOG-S0307.
S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307
Withdrawn
Southwest Oncology Group
2008-10-01
RATIONALE: Gathering information over time from imaging and laboratory tests of women
receiving bisphosphonates for breast cancer may help doctors learn more about long-term bone
quality and plan the best treatment. Tetracycline hydrochloride and demeclocycline
hydrochloride can mark the new growth of the bone, so it may be seen better under a
microscope.
PURPOSE: This clinical trial is studying long-term bone quality in women with breast cancer
enrolled on clinical trial SWOG-S0307.
Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
Completed
Eli Lilly and Company
Phase 4
2013-01-01
The purpose of this study is to determine how teriparatide or denosumab affects the bone of
postmenopausal women with osteoporosis after 3 months of treatment, as determined by a bone
biopsy sample taken from the iliac crest (upper part of the pelvis).
Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
Completed
Fundação de Amparo à Pesquisa do Estado de São Paulo
Phase 4
2014-08-01
The purpose of this study is to assess whether the switch from branded to generic warfarin or
between different generic warfarin tablets may cause fluctuation in the results of
coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing
them to unnecessary risks.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
